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Abstract Öz 
Purpose: Tumor and patient characteristics of 
neuroendocrine tumors (NET) significantly change 
between geographical locations that probably induced by 
environmental and genetic factors throughout the world. 
Therefore, reporting single center experience may help 
clarifying epidemiological view and improving decision-
making process.  
Materials and Methods: We performed retrospective 
analysis of 115 patients of NETs those who followed by 
Baskent University, department of Medical Oncology and 
department of General Surgery to record patients and 
tumors characteristics, treatment modalities, survival rates, 
and prognostic factors.   
Results: Median overall survival (OS) time for all group 
and localized NETs were 44 and 24 months, respectively. 
Most common primary site was found as gastrointestinal 
system and then pancreatic region. Curative surgical 
resection rate was 46% and 8.5% of patients presented 
with carcinoid syndrome. Liver metastasis was far the 
most common metastatic site compared to lung, bone, and 
lymph node metastasis. Over 70 percent of patients were 
treated with chemotherapy and somatostatin analogs. 
Conclusion: Patients with higher grade, male gender, and 
advanced age (>65 years old) had poor survival rate. 
However, relatively low number of patients and less usage 
of (<10%) of new treatment modalities created limitations 
for producing future directions from our study.  
Amaç: Nöroendokrin tümörler (NET) tümör ve hasta 
özellikleri, muhtemelen tüm dünyada çevresel ve genetik 
faktörlerin yol açtığı coğrafi alanlar arasında önemli 
değişiklik göstermektedir. Bu nedenle, tek merkez 
deneyimi bildirmek, epidemiyolojik görüşleri açıklığa 
kavuşturmaya ve karar verme sürecini geliştirmeye 
yardımcı olabilir 
Gereç ve Yöntem: Başkent Üniversitesi Tıbbi Onkoloji 
Anabilim Dalına başvuran ve takip edilen, tümör 
özelliklerini, tedavi yöntemlerini, sağkalım oranlarını ve 
prognostik faktörlerini kaydettiğimiz 82 NET tanılı 
hastanın retrospektif analizi yapılmıştır. 
Bulgular: Tüm grup ve lokal evredeki NET'lerin genel 
sağkalım süresi, sırasıyla 44 ve 24 aydır. En sık görülen 
primer tümör alanı gastrointestinal sistem ve daha sonra 
pankreas bölgesi olarak bulundu. Küratif cerrahi 
rezeksiyon oranı karsinoid sendrom ile başvuran 
hastaların%46'sında ve %8.5'inde idi.  Karaciğer metastazı 
akciğer, kemik ve lenf nodu metastazı ile 
karşılaştırıldığında en yaygın metastatik bölge idi. 
Hastaların %70'inden fazlası kemoterapi ve somatostatin 
analoğu ile tedavi edildi.  
Sonuç: Daha yüksek greydli, erkek cinsiyeti olan ve ileri 
yaşta (>65 yaş) hastalarda sağkalım oranı düşüktür. 
Bununla birlikte, nispeten düşük hasta sayısı ve yeni tedavi 
yöntemlerinin (<%10) daha az kullanımı, çalışmamızın 
gelecek için yönermeler üretebilmesi için sınırlamalar 
getirdi. 
Key words: Neuroendocrine tumors, outcomes, single 
center experience. 
Anahtar kelimeler: Nöroendokrin tümör, sonuçlar, tek 
merkez deneyimi. 
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INTRODUCTION 
Neuroendocrine tumors (NETs) are a group of 
clinically and pathologically distinct heterogeneous 
family of cancer1. Clinically significant annual 
incidence rate of NETs is reported between 2,5-5 
per 100,000 people, but its incidence rate increased 
in the last decades2,3. Moreover, with the relatively 
higher survival rates compared to adenocarcinomas, 
in current state NETs are more prevalent than 
pancreas and gastric cancers combined1. The 
common primary locations were gastrointestinal 
system and lungs; though NETs may originate from 
atypical locations like ovary, maxillary sinus, bone, 
and kidney and they may be presented with clinical 
syndrome resulted by excessive secretion of peptide 
hormones4.  
Management requires multidisciplinary approach 
with careful consideration of anatomic and 
histopathological characteristics of tumors. Total 
surgical excision is the only curative treatment 
modality, but more patients presented with 
advanced disease. The treatment modalities for 
these patients include cytotoxic chemotherapy, liver 
and tumor directed therapy, somatostatin analogs, 
and targeted therapy. However, optimal time and 
order of these expanding treatment options are not 
clear and we need to better understand tumor 
biology and biological behavior of the NETS to 
clarify to optimization. Using this retrospectively 
designed protocol, we aim to the study demographic 
characteristics, the overall, stage and site specific 
outcomes, prognostic factors, used treatment 
modalities and outcomes in 82 patients with NETs 
those who were followed in our center. 
MATERIALS AND METHODS 
Baskent University patient database was searched 
for international ICD codes NETs between the 
years of 2006 and 2013. Consecutive 115 
neuroendocrine tumor patients those who were 
followed at Baskent University Medical Oncology 
and General Surgery departments were identified 
after obtaining ethical clearance from ethical 
committee. Among those, 82 patients with NET 
were enrolled for this study. The reasons for 
exclusions (n=43) included primary lung tumors 
(n=28) and non-follow-up patients15. 
The tumors were graded as G1, G2, or G3 
following the WHO (version 2010) classification. 
Grade 1 and 2 tumors represent good differential 
tumors, grade 3 tumors represent poorly 
differentiated tumors. Ki-67 and proliferation index 
were taken into account when classifying the 
tumors. WHO classification is indicated in Table-1. 
Table 1. WHO Grading Systems for 
gastroenteropancreatic (GEP) and Pulmonary NETs 
 Grade Pulmonary 
NETs 
Proliferative 
Rate 
GEP NETs 
Proliferative 
Rate 
Well-
differentiated 
G1 (low 
grade) 
< 2 
mitoses/10 
hpf AND 
No necrosis 
<2 
mitoses/10 
hpf 
AND 
<3% Ki-67 
index 
G2 
(intermediate 
grade) 
2-10 
mitoses/10 
hpf OR 
necrosis 
2-20 
mitoses/10 
hpf 
OR 
3%-20% Ki-
67 index 
Poorly 
differentiated 
G3 (high 
grade) 
>10 
mitoses/10 
hpf 
>20 
mitoses/10 
hpf 
 OR 
> 20% Ki-67 
index 
Data collection 
The clinical and laboratory information of the 
patients was transferred safely from the electronic 
records to the SPSS form. Demographic and 
clinicopathologic variables of the patients were 
determined by considering the disease characteristics 
and follow-up criteria included in the international 
guidelines. Demographics, clinicopathological 
characteristics, radiographic data and treatment 
modalities of patients were extracted from electronic 
medical records for all 115 patients. In all cases, 
immunohistochemistry for synaptophysin, 
chromogranin and Ki-67 was performed in Baskent 
University Department of Pathology. Conventional 
tomography PET CT was used for staging of the 
patients 
Statistical analysis 
All results were presented as rate for categorical 
values, or mean and median for continuous 
variables. Survival curves were estimated by the 
Kaplan-Meier method and log-rank tests were used 
for univariate statistical comparisons. Overall 
survival (OS) was calculated from the date of 
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histological diagnosis of NETs to the date of the last 
visit or death. The Cox proportional hazards model 
was used to determine the variables associated with 
OS of Neuroendocrine tumors. Adjusted Hazard 
ratio (HR) and %95 confidence interval (95% CIs) 
were used for estimation. All data were analyzed 
using SPSS version 17.0 statistics were made by 
using SPSS version 17.0 and a p value of <0.05 was 
considered statistically significant.  
RESULTS 
Patients characteristics 
Of the 82 patients, there were 46 male patients 
(56%). Median age was 55 years (range 28-78). 
GEP-NETs, lung and other localizations 
neuroendocrine tumors were found in 45 (55.6 %), 
13(16%), and 23 (28 %) patients, respectively. 
Though, GEP-NETs in 45 (55.6%) patients 
constitutes most often localization, rare localizations 
were present in Table 2. Curative surgery was 
performed in 38 (46%) patients, including 5 
carcinoid tumors; the remaining 44 (54%) of 
patients were not appropriate for the curative 
resection. There were 7 (8.5%) patients those who 
presented with symptoms of excess peptide 
hormones. Profound diarrhea was most common 
symptom and seen in 4 (4.9%) patients. Out of the 7 
patients, 2 of them treated with curative resection 
and 5 of them treated symptomatically with 
somatostatin analogs. 
Table 2. Tumor localizations of 82 NETs  
Localizations Percentage % 
Gastric (n:20) 24 
Pancreas (n:16) 19 
Lung (n:13) 16 
Primary unknown (n:10) 12 
Appendix (n:5) 6 
Small bowel (n:4) 5 
Rectum (n:4) 5 
Bone (n:2) 2,5 
Maxililary sinuses (n:2) 2,5 
Colon (n:1) 1 
Kidney (n:1) 1 
Bladder (n:1) 1 
Adrenal gland ( n:1) 1 
Ovarian (n:1) 1 
Paravertebral area (n:1) 1 
Staining for the synaptophysin and chromogranin 
were positive in 65 (79%) and 65 (79%) patients.  
While, 60 patients were positive for both 
synaptophysin and chromogranin, 5 patients in each 
group were positive for either synaptophysin or 
chromogranin only. Grade, Ki 67 and mitotic rate 
were evaluated in 79 (96.3%), 48 (58.5%), and 29 
(35.4%) patients, respectively (Table 3). Metastases 
to liver were found in 40 (48.8%) patients and liver 
was the far commonest metastatic site for the whole 
group.  
Table-3. WHO classification and ki-67 indexes of 
tumor 
 Percentage (%) 
WHO classification  
Grade 1 32 (n:27) 
Grade 2  25 (n:20) 
Grade 3  39 (n:32) 
Un-known  4  (n:3) 
Ki-67 indices  
<%2 31 (n:25) 
%2-20 16 (n:13) 
>% 20 12 (n:10) 
Unknown 41 (n:34) 
Treatments and outcomes 
Mean follow-up time was 21.3 months (range 16.9-
25.6) and 45 (56%) patients were died during the 
study period.  Out of the 82 patients, 38 (46%) 
patients were treated with curative surgical resection. 
There were 10 patients with grade 3 tumor and 
these patients were treated with adjuvant platin-
etoposide combination chemotherapy. There were 
17 patients with grade 1 tumor those who showed 
excellent prognosis with no relapse during 
surveillance. In addition, there were 8 patients with 
grade 2 tumor, those 3 of them were treated with 
the systemic chemotherapy (platin-etoposide), 
showed also excellent prognosis without disease 
relapse. Median OS time was estimated 44 months 
[31.7- 56.3 (95 % CI)] (figure-1). Mitotic index and 
age showed statistically significant effect on OS in 
univariate analysis with p=0.007 and p=0.05, 
respectively. However, in multivariate analysis, 
WHO grade, age, and sex showed statistically 
significant effect on OS with p=0.015, p=0.003, and 
p=0.027, respectively were detailed in Table 4 for 
the curatively resected patients 
For the whole group, treatment modalities were 
systemic chemotherapy, somatostatin analogs, 
metastectomy, trans arterial chemoembolization 
(TACE), radionuclide treatment, everolimus, and 
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sunitinib in 36 (43%), 34 (41.5%), 1 (1.2%), 7 
(8.5%), 9 (11%), 3 (3.7%), and 3 (3.7%) patients, 
respectively. The most common cytotoxic 
chemotherapy protocols were cisplatin+etoposid, 5-
FU + Dacarbasine + epirubicin, capesitabin 
+temozolamid and carboplatin + irinotecan 
combinations.Though, the liver is most common 
site; liver, bone, and lymph node metastases were 
found in 40 (48.8%), 8 (9.8%), and 3 (3.7%) 
patients, respectively. Median OS was estimated as 
24 months [13.8- 34.2 (95% CI)] for whole group 
(figure-2). Mitotic index, sex, Ki-67, and WHO 
grade showed statistically significant effect on OS in 
univariate analysis with p=0.003, p=0.007, p=0.019, 
and p=0.027, respectively. However, in multivariate 
analysis, WHO grade, sex and age showed 
statistically significant effect on OS with p=0.028, 
p=0.027, and p=0.011, respectively (Table 5). 
DISCUSSION  
NETs are probably one of the most heterogeneous 
group of cancers and difficult to grasp into a 
universally accepted classification system for more 
than 3 decades5. Indeed, all commonly used 
classification systems using proliferation markers, 
tumor stage, and primary tumor localization [GEP-
NET’s (gastric mucosa, the small and large intestine, 
the rectum and pancreas) and lung] aim to establish 
clear epidemiologic view and precision in treatment 
decision 6-8. Recent epidemiological studies showed 
increase rate of NETs in Europe and United States 
and now, prevalence of NETs is higher than all 
gastrointestinal cancers except colon cancer5. 
However, studies also showed tumor and patients 
characteristics, prognostic factors, treatment 
modalities, and survival rates significantly differ 
between countries, even sometimes differ in the 
same country3,9,10. Here, our study provides valuable 
insight and showed that NETs are not benign 
disease, though have a slower clinical course 
compared to adenocarcinoma with median OS time 
of 24 months. Over 50 percent of NETs are GEP-
NETs. In addition, WHO grade, sex, and age have 
significant effect on OS in multivariate analysis.  
 
  
Figure-1: Median OS time was estimated 44 months 
[31.7- 56.3 (95 % CI)] who treated with curative 
surgical resection 
Figure 2. Median OS was estimated as 24 months 
[13.8- 34.2 (95% CI)] for whole group. 
 
Table 4. Multivariate analysis of prognostic factors for overall survival who treated with curative surgical 
resection. 
Variable Univariate analysis Multivariate analysis 
 p HR 95 % Cl p 
Mitotic index 0.007 0.08 (0.86-10.26) 0.084 
Age 0.05 24.28 (2.99-197.03) 0.03 
Grade 0,055 4.78 (1.35-16.86) 0.015 
Sex 0.138 0.14 (0.03-0.78) 0.027 
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Table 5. Multivariate analyseis of prognostic factors for overall survival for whole group 
Variable Univariate analysis Multivariate analysis 
 p OR 95 % Cl p 
Mitotic index 0.003 1.26 (0.88-1.81) 0.212 
Sex 0.007 0.47 (0.24-0.92) 0.027 
Ki-67 0.019 0.70 (0.44-1.12) 0.141 
Grade 0.027 1.94 (1.07-3.49) 0.028 
Age 0,007 1.96 (1.16-3.29) 0.011 
OR: odds ratio; CI: confidence interval 
 
The heterogeneous nature of disease complicates 
data collection and clarity in literature. Tumor 
localization, grade, differentiation, and peptide 
hormone secretion are major contributors to 
treatment decision. In particular, pancreatic vs. non-
pancreatic anatomic site is key element with regard 
of tumor localization. Yao et al. and Dogan et al. 
reported lung was the most common site, although, 
Maggard et al. and Lawrance et al. reported more 
than half of the all NETs were GEP-NETs3,5,11,12. 
While tumor localization has predictive effect on 
response rate, some of these studies showed also 
statistically significant effect of tumor localization 
on OS 1,5. GEP-NETs is most common localization 
in current study (55.6%) and statistical analysis failed 
to show significant effect of tumor localization on 
OS.  
Median survival rate is better in well-differentiated 
NETs compared to poorly differentiated ones, yet 
surgical excision is the main treatment strategy for 
all grade local disease. Adjuvant treatment can be 
considered for high-grade tumors in particular for 
the lung NETs13.  We observed excellent survival 
rates (5-year survival of 87%– 90%) for grade I 
NETs after curative resection without any 
recurrence. With regard to grade 2 NETs, out of 8 
patients, 3 patients treated with adjuvant platin-
etoposide chemotherapy. Similar to grade I tumors, 
there is no relapse for these patients, but these 
group was too small to reach the conclusion about 
adjuvant therapy. All patients with grade 3 NETs 
receive adjuvant platin-etoposide with high rate of 
recurrence and lowest OS time of 5-year survival 
rate of 15%–57%).  
Median age was 55 years old. In multivariate 
analysis, statistical analysis showed being over 65 
years old, male gender, and higher grade were strong 
negative prognostic factor for localized NETs. In 
contrast to most studies, we noted male 
predominance in present study3. These results are in 
agreement with studies demonstrating the higher 
grade association of lower survival, although age and 
sex are not well defined prognostic factors in 
literature for localized NETs1,14. 
At advanced stage, five-year OS rate was reported 
50-70% and 45-60% for all patients and GEP-
NETs, respectively. Yao et al. showed that tumor 
differentiation, primary tumor localization, 
metastatic sites, and histological grade were major 
prognostic factor in advanced states14. Yao et al also 
reported that patients with male gender and 
advanced age (over 60 years old) lower survival 
rate14. In a report by Wang et al, the most common 
primary tumor site was pancreas and liver was the 
predominant site of NET metastases7,15. With regard 
to GEP-NETs, pancreatic primaries had worse 
survival rate compared to gastric, intestinal and 
colonic primaries. However, Lawrence et al reported 
an epidemiologic study which included around 
50.000 patients, and stated that despite poorer five 
year survival rate for pancreatic cancer compared to 
colon cancer, median OS of pancreatic NETs was 
higher (18.9 months vs. 10.3 months) than colonic 
primaries5. This initial sharp decrease in survival 
curve in pancreatic NETs suggest internal 
heterogeneity of NETs even with same primaries 
and we need urgent molecular markers in precision 
decision-making process. Mean follow-up time and 
median OS were estimated as 21.3 and 24 months, 
respectively. Liver is the most common site for the 
metastases (48.8%). In multivariate analysis, WHO 
grade, sex and age showed statistically significant 
effect on OS with p: 0.028, p: 0.027, and p: 0.011, 
respectively. Results of current study compatible 
with literature showed that, higher grade, male 
gender, and advanced age (over 65 years old) were 
poor prognostic factor for patients with NETs, 
although we failed to show statistically significant 
effect of primary tumor localization on OS.  
A limitation of our study is that majority of patients 
treated with chemotherapy and somatostatin 
analogs, yet less than 10% of whole group had 
chance to reach new treatment modalities like 
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peptide receptor radionuclide treatment and tyrosine 
kinase inhibitors. Hence, we couldn’t make any 
suggestion about real time effect of these new 
treatment modalities in our patients. One other 
limitation of the current study is that relatively low 
number of patients compared to multicenter studies 
and large epidemiological studies in literature. It is 
possible that low number of patients is the reason 
for underestimation of prognostic role of primary 
locations. 
In conclusion, we found an independent statistically 
significant association between survival rate and age, 
sex, and histological grade in multivariate analysis. 
These associations were evident in both localized 
and advanced NETs. Our findings support the 
current literature and compatible with universally 
used algorithms. Our findings highlight the clinical 
importance and heterogeneous nature of NETs that 
have to be treated individually, case by case, with 
multidisciplinary approach.    
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